Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes
- PMID: 29456108
- DOI: 10.1016/j.bmcl.2018.02.013
Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes
Erratum in
-
Erratum to "Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes" Bioorg. Med. Chem. Lett. 28 (2018) [841-846].Bioorg Med Chem Lett. 2018 May 15;28(9):1676-1678. doi: 10.1016/j.bmcl.2018.03.053. Epub 2018 Mar 28. Bioorg Med Chem Lett. 2018. PMID: 29605534 No abstract available.
Abstract
The discovery of a novel series of N-arylpyrroles as agonists of GPR120 (FFAR4) is discussed. One lead compound is a potent GPR120 agonist, has good selectivity for related receptor GPR40 (FFAR1), has acceptable PK properties, and is active in 2 models of Type 2 Diabetes in mice.
Keywords: DIO mouse; FFAR4; GPR120; GPR40; N-arylpyrrole; Type 2 diabetes; oGTT.
Copyright © 2018 Elsevier Ltd. All rights reserved.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Medical